Guo N, Wang WQ, Gong XJ, Gao L, Yang LR, Yu WN, Shen HY, Wan LQ, Jia XF, Wang YS, Zhao Y. Study of recombinant human interleukin-12 for treatment of complications after radiotherapy for tumor patients. World J Clin Oncol 2017; 8(2): 158-167 [PMID: 28439497 DOI: 10.5306/wjco.v8.i2.158]
Corresponding Author of This Article
Dr. Yi-Shan Wang, Center for Tumor Treatment, People’s Liberation Army 107th Hospital, 7 Zhichu South Road, Yantai 264002, Shandong Province, China. wangyishan288@163.com
Research Domain of This Article
Medical Laboratory Technology
Article-Type of This Article
Clinical Trials Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Apr 10, 2017; 8(2): 158-167 Published online Apr 10, 2017. doi: 10.5306/wjco.v8.i2.158
Study of recombinant human interleukin-12 for treatment of complications after radiotherapy for tumor patients
Na Guo, Wen-Qin Wang, Xiao-Jing Gong, Lei Gao, Li-Rong Yang, Wei-Na Yu, Hong-Yu Shen, Ling-Qin Wan, Xi-Feng Jia, Yi-Shan Wang, Yi Zhao
Na Guo, Xiao-Jing Gong, Lei Gao, Li-Rong Yang, Wei-Na Yu, Hong-Yu Shen, Ling-Qin Wan, Xi-Feng Jia, Yi-Shan Wang, Center for Tumor Treatment, People’s Liberation Army 107th Hospital, Yantai 264002, Shandong Province, China
Wen-Qin Wang, Academy of Military Medical Sciences, Sanatorium for Retired Cadres, Beijing 100039, China
Yi Zhao, Kang Litai Pharmaceutical Co. Ltd., Qingdao 266001, Shandong Province, China
Author contributions: Wang YS and Zhao Y contributed to the conception of the study; Guo N and Wang WQ contributed significantly to analysis and manuscript preparation; Guo N, Gao L and Shen HY performed the data analyses and wrote the manuscript; Wang WQ and Gong XJ helped perform the analysis with constructive discussions; Yang LR and Yu WN collected specimens and detected indexes; all the authors contributed to this article.
Institutional review board statement: This study was reviewed and approved by the scientific ethical committee of the Hospital. All operations were performed according to international guidelines concerning the care and treatment of cancer patients.
Informed consent statement: Patients were informed of the purpose of the experiment and agreed to treatment with rhuIL-12. Informed consent was obtained in all cases, and protocols were approved by the scientific ethical committee of the Hospital.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: No additional unpublished data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Yi-Shan Wang, Center for Tumor Treatment, People’s Liberation Army 107th Hospital, 7 Zhichu South Road, Yantai 264002, Shandong Province, China. wangyishan288@163.com
Telephone: +86-535-2933528 Fax: +86-535-2933500
Received: October 11, 2016 Peer-review started: October 14, 2016 First decision: November 14, 2016 Revised: December 14, 2016 Accepted: January 2, 2017 Article in press: January 4, 2017 Published online: April 10, 2017 Processing time: 178 Days and 0.2 Hours
Core Tip
Core tip: Recombinant human interleukin-12 (rhIL-12) is a new kind of biological agent secreted by Chinese hamster ovary cells. Study has shown that it has the advantage of promoting recovery of hematopoietic function, regulating the body’s immunity and inhibiting angiogenesis growth. At present, the research of rhIL-12 stays in the foundational realm and in animal experimentation. In our study, however, there were 100 patients with large or numerous tumors (more than two) and who received precision radiotherapy (Cyber knife or image-guided radiotherapy). The results showed that rhIL-12 can prevent radiation damage, improve hematopoietic function, regulate immunity, reduce the side effect of radiotherapy and improve the quality of life of patients.
